ArticleThe pharmacogenomics journal2025
mLeveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes.
Article in The pharmacogenomics journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Type 2 diabetes (T2D) is a complex, polygenic disease with substantial health impact. Despite extensive genome-wide association studies (GWAS) identifying risk loci, therapeutic translation remains limited. We applied a Bayesian Linear Regression (BLR) multi-trait gene set model to prioritize druggable gene sets, integrating GWAS summary statistics with drug-gene interaction data from the Drug Gene Interaction Database (DGIdb). For each drug group, defined at the ATC 4th level, we calculated posterior inclusion probabilities (PIP) to assess relevance. Known antidiabetic agents showed strong associations with T2D, validating the model. Additionally, carboxamide derivatives, fibrates, uric acid inhibitors, and various immunomodulatory and antineoplastic agents demonstrated significant genetic relevance. Gene-level analyses highlighted key T2D-associated genes, including PPARG, KCNQ1, TNF, and GCK. Notably, bezafibrate, a PPAR pan-agonist, demonstrated substantial genetic overlap with T2D loci, supporting its potential in metabolic disease. This study introduces a genetically informed pipeline for drug repurposing based on multi-trait gene set analysis.
Indexed as
Identifiers
41224746What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.